Experience about discontinuation of eculizumab in patients with CFB and C3 mutations has not been published, but these 2 mutations lead to end-stage renal disease in about 60% to 70% of patients and recurrence risk after kidney transplantation was found significantly high.[1,17] Therefore, approach to patients with these mutations should be similar to those with CFH mutations. This evidence concerns the gene CFB and stage 5 chronic kidney disease.